Pharmacological and physiotherapeutic methods of treating non-exudative age-related macular degeneration

Close metadata

Recommended articles:

Management of patients with treatment-resistant neovascular age-related macular degeneration. Russian Annals of Ophthalmology. 2024;(6):63-68

Neuroprotective therapy for age-related macular degeneration. Russian Annals of Ophthalmology. 2024;(6):152-158

Possibilities of using cytoprotectors in complex therapy of chronic coronary heart disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(4):410-419

Determination of indications for antioxidant therapy at the stage of pregravidar preparation of patients with early fetal loss in anamnesis. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):66-70

Dynamics of motor and functional disorders in the early recovery period after ischemic stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):13-22

Oxidative stress in the pathogenesis of chronic headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):35-40

Alterations in the activity of glutathione-dependent enzymes in erythrocytes of patients with acute pancreatitis of varying severity. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):10-15

Application of modern methods for activation of brain functions in obese patients (literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):54-61

Complications after Laser Treatment. Journal of Venous Disorders. 2024;(4):317-327

The effectiveness of rehabilitation measures using the drug Cortexin in children with neuropsychiatric pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):86-92

The non-exudative form of age-related macular degeneration (AMD) is a disease with long-term progression for which effective treatments have not been found. Many studies are being conducted to find effective drugs to prevent the appearance of drusen and increase in RPE atrophy area, which could help avoid this more dangerous form of AMD. The main drugs (nutraceuticals) that are used to treat the dry form of AMD are lutein, zeaxanthin and omega-3 fatty acids. Additionally, treatment may include nanosecond laser therapy for drusen in advanced AMD, panretinal subthreshold micropulse laser exposure for atrophic AMD, as well as microcurrent stimulation. Further research in this area should be aimed at understanding all the pathogenetic mechanisms associated with the development of AMD, and developing new approaches to the treatment of this disease including physiotherapy.

Keywords:

age-related macular degeneration

drusen

lipofuscin

oxidative stress

lutein

zeaxanthin

laser treatment

physiotherapy

Authors:

Drakon A.K.

Research Institute of Eye Diseases

Kurguzova A.G.

Krasnov Research Institute of Eye Diseases

ORCID: 0000-0002-3990-4491

Sheludchenko V.M.

Krasnov Research Institute of Eye Diseases

ORCID: 0000-0001-5958-3018

Korchazhkina N.B.

Russian research center of surgery named after academician B.V. Petrovsky;
The Moscow state medical University named after A.I. Evdokimov of the Ministry of health of Russia

ORCID: 0000-0002-9804-7725

Received:

24.03.2021

Accepted:

09.05.2021

List of references:

Congdon N, O’Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Archives of Ophthalmology. 2004;122(4):477-485. https://doi.org/10.1001/archopht.122.4.477
Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738. https://doi.org/10.1016/s0140-6736(12)60282-7
Stahl A. The diagnosis and treatment of age-related macular degeneration. Deutsches Arzteblatt International. 2020;117(29-30):513-520. https://doi.org/10.3238/arztebl.2020.0513
Klein R, Klein BE, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: The Beaver Dam Eye Study. American Journal of Ophthalmology. 2006;142(4):539-549. https://doi.org/10.1016/j.ajo.2006.06.015
Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1997;104(1):7-21. https://doi.org/10.1016/s0161-6420(97)30368-6
Efendieva MKh, Rudko AS, Karpilova MA. Pathophysiological aspects of age-related macular degeneration and glaucoma. Natsional’nyj zhurnal glaukoma. 2016;15(3):81-92. (In Russ.).
Shelankova AV, Budzinskaya MV, Andreeva IV, Afanasyeva MA. Real clinical practice of antiangiogenic therapy in patients with age-related macular degeneration. Retrospective analysis of functional results. Vestnik oftal’mologii. 2020;136(4):207-213. (In Russ.). https://doi.org/10.17116/oftalma2020136042207
Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Archives of Ophthalmology. 2010;128(3):349-358. https://doi.org/10.1001/archophthalmol.2010.18
Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. American Journal of Epidemiology. 2002;156(7):589-598. https://doi.org/10.1093/aje/kwf092
Mares-Perlman JA, Brady WE, Klein R, Van den Langenberg GM, Klein BE, Palta M. Dietary fat and age-related maculopathy. Archives of Ophthalmology. 1995;113(6):743-748. https://doi.org/10.1001/archopht.1995.01100060069034
Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 2003;110(6):1273-1280. https://doi.org/10.1016/s0161-6420(02)01448-3
Warburton S, Southwick K, Hardman RM, Secrest AM, Grow RK, Xin H, Woolley AT, Burton GF, Thulin CD. Examining the proteins of functional retinal lipofuscin using analysis as a guide for understanding its origin. Molecular Vision. 2005;11:1122-1134. https://doi.org/10.1016/j.exer.2005.01.007
Sheremet NL, Andreeva NA, Zhorzholadze NV, Shmelkova MS, Fomin AV. Structural and functional changes in the retina and optic nerve in patients with toxic optic neuropathy caused by acute methanol poisoning. Vestnik oftal’mologii. 2020;136(4):243-250. (In Russ.). https://doi.org/10.17116/oftalma2020136042243
Budzinskaya MV, Durzhinskaya MKh. Differential diagnosis of hydroxychloroquine-induced retinal damage. Vestnik oftal’mologii. 2020;136(4):265-271. (In Russ.). https://doi.org/10.17116/oftalma2020136042265
Strauss O. The retinal pigment epithelium in visual function. Physiological Reviews. 2005;85(3):845-881. https://doi.org/10.1152/physrev.00021.2004
Sheremet NL, Ronzina IA, Mikaleyan AA, Zhorzholadze NV, Plyukhova AA, Kiselev SL. Morphological and functional indicators of retinal pigment epithelium and photoreceptor apparatus in inherited retinal diseases. Vestnik oftal’mologii. 2020;136(4-2):183-192. (In Russ.). https://doi.org/10.17116/oftalma2020136042183
Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Experimental Eye Research. 2005;80(5):595-606. https://doi.org/10.1016/j.exer.2005.01.007
Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacological Reports: PR. 2006;58(3):353-363. https://doi.org/10.1037/e606252007-001
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Archives of Ophthalmology. 2001;119(10): 1417-1436. https://doi.org/10.1001/archopht.119.10.1417
Age-Related Eye Disease Study 2 Research Group. Lutein+zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013; 309(19):2005-2015. https://doi.org/10.3410/f.718007638.793478653
Fayzrakhmanov RR, Budzinskaya MV. Macular pigments in retinal degenerative processes. Vestnik oftal’mologii. 2018;134(5):135-140. (In Russ.). https://doi.org/10.17116/oftalma2018134051135
Gamidov AA, Baryshev KV, Perevozchikov KA, Surnina ZV. Atomic force microscopy in the study of retinal structure. Vestnik oftal’mologii. 2020;136(4): 251-257. (In Russ.). https://doi.org/10.17116/oftalma2020136042251
Khan KN, Mahroo OA, Khan RS, Mohamed MD, McKibbin M, Bird A. Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Progress in Retinal and Eye Research. 2016;53: 70-106. https://doi.org/10.1016/j.preteyeres.2016.04.008
Afanasyeva MA, Budzinskaya MV, Plyukhova AA. Current understanding of pachychoroid spectrum diseases. Vestnik oftal’mologii. 2019;135(5):293-298. (In Russ.). https://doi.org/10.17116/oftalma2019135052293
Kiseleva TN, Lagutina YuM, Kravchuk EA. Modern aspects of pathogenesis, clinic and treatment of non exudative forms of age-related macular degeneration. RMZh. Klinicheskaya oftal’mologiya. 2006;3:99. (In Russ.).
Sacconi R, Corbelli E, Querques L, Bandello F, Querques G. A Review of Current and Future Management of Geographic Atrophy. Ophthalmology and Therapy. 2017;6(1):69-77. https://doi.org/10.1007/s40123-017-0086-6
Velilla S, García-Medina JJ, García-Layana A, Dolz-Marco R, Pons-Vázquez S, Pinazo-Durán MD, Gómez-Ulla F, Arévalo JF, Díaz-Llopis M, Gallego-Pinazo R. Smoking and age-related macular degeneration: review and update. Journal of Ophthalmology. 2013;2013:895147. https://doi.org/10.1155/2013/895147
Lee S, Song SJ, Yu HG. Current smoking is associated with a poor visual acuity improvement after intravitreal ranibizumab therapy in patients with exudative agerelated macular degeneration. Journal of Korean Medical Science. 2013;28(5):769-774. https://doi.org/10.3346/jkms.2013.28.5.769
Handa JT, Bowes Rickman C, Dick AD, Gorin MB, Miller JW, Toth CA, Ueffing M, Zarbin M, Farrer LA. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nature Communications. 2019;10(1):3347. https://doi.org/10.1038/s41467-019-11262-1
Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, McGuinness MB, Fletcher EL, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Lek JJ, Harper CA, Wickremasinghe SS, Sandhu SS, Baglin EK, Sharangan P, Braat S, Luu CD; Laser Intervention in Early Stages of Age-Related Macular Degeneration Study Group. Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD randomized controlled clinical trial. Ophthalmology. 2019; 126(6):829-838. https://doi.org/10.1016/j.ophtha.2019.07.016
Luttrull JK, Sinclair SH, Elmann S, Chang DB, Kent D. Slowed Progression of Age-Related Geographic Atrophy Following Subthreshold Laser. Clinical Ophthalmology. 2020;14:2983-2993. https://doi.org/10.2147/opth.s268322
Sehic A, Guo S, Cho KS, Corraya RM, Chen DF, Utheim TP. Electrical stimulation as a means for improving vision. The American Journal of Pathology. 2016;186(11):2783-2797. https://doi.org/10.1016/j.ajpath.2016.07.017
Ioileva EE, Filatova EV, Golubeva OV, Gavrilova NA, Gadzhieva NS. Fizioterapevticheskaya reabilitatsiya patsientov s vozrastnoj makulyarnoj degeneratsiej: Uchebnoe posobie dlya klinicheskikh ordinatorov, vrachej-oftal’mologov i vrachei-fizioterapevtov. M.: MGMSU im. A.I. Evdokimova; 2017:19-28. (In Russ.).

Close metadata